In fact, GHRH antagonists suppress the growth in vivo of many types of cancer, including breast, pancreatic and colorectal carcinomas, gastric and prostate cancer, lung carcinomas, malignant pleural mesotheliomas, and malignant glioblastomas [15,16,17,18,19]. This evidence concerns the gene GHRH and cancer.